MEVAC Idea.
From a single facility to a global presence in 51+ countries, MEVAC's growth reflects our unwavering dedication to innovation and impact.
MEVAC Idea.
MEVAC B1 opening & operation.
Cell Culture Monolayer cells based Vaccines Production.
MEVAC B2 with 2 additional Production lines for Poultry Vaccines.
T.C Fermentation vaccine production lines.
Partnership with kemin industries (USA) for Market Authorization Of MEVAC Vaccines Globally.
Saudi Arabia Scientific Office Operation.
MEVAC B3 Opening with 2 Additional Avian influenza Production Lines.
MEVAC B4 opening for robust Recombinant Vaccine Full Automated Production lines.
Leadership with a shared passion for science and global impact.
Since 2022, MEVAC partners with Kemin Industries, a global leader in biotechnology This partnership fuels our: R&D Advancements: With Kemin’s scientific expertise and resources.
Global Reach: Leveraging Kemin’s distribution networks to expand into new markets. Sustainability: Shared commitment to eco friendly production and animal welfare
MEVAC crafts science-driven vaccines and services that sustain the heartbeat of animal and human health, empowering a safer, healthier world and transforming the quality of life through innovation and care.
To continuously develop vaccines and services grounded in cutting-edge science, tailored to the evolving needs of animal and human health. To improve customer journey through efficient, sustainable solutions achieving customer satisfaction.
To lead with agile research and development practices with rapid response to emerging health challenges and drive impactful innovation.
To uphold the highest global standards in quality, safety, and efficacy across all our vaccines and services, ensuring trust and protection at every step with sustainability compliance.